High-efficiency Transduction and Correction of Murine Hemophilia B Using AAV2 Vectors Devoid of Multiple Surface-exposed Tyrosines
Open Access
- 1 December 2010
- journal article
- Published by Elsevier in Molecular Therapy
- Vol. 18 (12), 2048-2056
- https://doi.org/10.1038/mt.2010.172
Abstract
No abstract availableKeywords
This publication has 48 references indexed in Scilit:
- Oral delivery of bioencapsulated coagulation factor IX prevents inhibitor formation and fatal anaphylaxis in hemophilia B miceProceedings of the National Academy of Sciences, 2010
- Impact of the Underlying Mutation and the Route of Vector Administration on Immune Responses to Factor IX in Gene Therapy for Hemophilia BMolecular Therapy, 2009
- Improved Induction of Immune Tolerance to Factor IX by Hepatic AAV-8 Gene TransferHuman Gene Therapy, 2009
- High-efficiency Transduction of the Mouse Retina by Tyrosine-mutant AAV Serotype VectorsMolecular Therapy, 2009
- Tyrosine-phosphorylation of AAV2 vectors and its consequences on viral intracellular trafficking and transgene expressionVirology, 2008
- Treatment of Leber Congenital Amaurosis Due toRPE65Mutations by Ocular Subretinal Injection of Adeno-Associated Virus Gene Vector: Short-Term Results of a Phase I TrialHuman Gene Therapy, 2008
- Human gene therapy for RPE65 isomerase deficiency activates the retinoid cycle of vision but with slow rod kineticsProceedings of the National Academy of Sciences, 2008
- Next generation of adeno-associated virus 2 vectors: Point mutations in tyrosines lead to high-efficiency transduction at lower dosesProceedings of the National Academy of Sciences, 2008
- Safety and Efficacy of Gene Transfer for Leber's Congenital AmaurosisNew England Journal of Medicine, 2008
- Effect of Gene Therapy on Visual Function in Leber's Congenital AmaurosisNew England Journal of Medicine, 2008